Clinical trial
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or…
NCT00003214 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003214 |
|---|---|
| Title | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer |
| Official title | Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, in vitro sensitivity-directed chemotherapy, paclitaxel |
| Enrollment | 300 |
| Start date | Jul 1, 1996 |
| Primary completion | Apr 1, 2000 |
| Completion | Apr 1, 2000 |
| First posted | Aug 2, 2004 |
| Last update posted | May 15, 2019 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: